Loading...
NPI 1376548271 · Salt Lake City, UT · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Associated Regional And University Pathologists Inc is a clinical medical laboratory provider located in Salt Lake City, Utah. This profile covers 291 Medicare and 268 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Associated Regional And University Pathologists Inc |
| Address | 500 Chipeta Way |
| City | Salt Lake City |
| State | UT |
| ZIP | 84108 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 16, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $8.1M |
| Medicare | $1.6M |
This provider’s payer mix is heavily skewed toward Medicaid: total Medicaid revenue on file is $8.1M compared with $1.6M in Medicare revenue, so Medicaid is the principal source of billed revenue for this entity. Analysts should treat the provider as effectively Medicaid-dominant when evaluating revenue risk and network exposure.
Medicare revenue is concentrated in a small set of molecular and genetic codes: the top three Medicare codes account for 38.2% of Medicare revenue, led by 81479 ($219.4K, 22.0%), followed by 81206 ($110.9K, 11.1%) and 81263 ($50.9K, 5.1%). This concentration points to a specialty mix where higher-pay molecular pathology and targeted gene assays contribute a disproportionate share of Medicare dollars.
The provider’s Medicare code mix indicates a substantive molecular/genomic testing operation: high-revenue entries include 81479 (molecular pathology), 81206 (BCR/ABL1 testing), and 81450 (genomic sequence panel), and recurring items such as 81270, 81256, and 81170 show capability in targeted mutation analysis and oncology-associated assays. Together these codes suggest the lab performs both complex sequencing and a suite of related hematolymphoid/oncology tests rather than only routine chemistry.
Competitive standing on Medicare is mixed: the provider ranks relatively high nationally on several specialized genetic tests (for example 81206 is #8 of 89, 92th percentile; 81263 is #7 of 48, 87th percentile), while volumes for some broad molecular codes such as 81479 are described as typical or unremarkable at the national level (81479 is #22 of 80, 73th percentile). This pattern implies the lab is a meaningful national participant in specific niche assays but not uniformly dominant across all molecular codes.
Medicaid revenue is driven by high-volume toxicology and lead testing: the top three Medicaid codes account for 35.2% of Medicaid revenue and are led by G0480 ($869.2K, 17.6%), 83655 ($478.3K, 9.7%) and 87902 ($390.7K, 7.9%). The state-level labels emphasize this operational focus—83655 is an extreme outlier in-state (rank #1 of 41, 100th percentile) and G0480 is notably above typical state volume (rank #2 of 42, 98th percentile).
Operational scale on Medicaid is substantial in volume-based assays: examples include 83655 with 34.2K claims and G0480 with 13.4K claims, and other high-claim services such as 80307 (12.2K claims) and multiple high-count STI/COVID and hormone assays. These claim counts indicate the provider serves high-throughput public-health and screening use cases in-state, not just low-volume specialty work.
The provider is a dominant state-level player across many routine and screening tests: numerous Medicaid codes are at or near the top in-state (examples include 83655, 84403, 84402, 86317, 83516 and 87510 all ranked #1 in-state or flagged as notably above typical), which supports characterization as a major supplier for Utah Medicaid for toxicology, lead screening, hormones, and several infectious disease assays.
The billing record aligns with an established laboratory: the NPI was enumerated on 2005-06-16 (~21 years ago), reflecting long tenure in the market. Combined with large Medicaid volume and top-in-state ranks, this suggests entrenched operational capacity and longstanding referral or sample-sourcing relationships within the state payer network.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
291 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 660 | $330 | $219.4K |
| 81206 | The lab analyst performs the technical lab test to evaluate the major breakpoint gene sequence BCR/ALB1 that occurs on chromosome 22 due to translocation, which involves breakage and reforming of an… | 690 | $160 | $110.9K |
| 81263 | The lab analyst performs the technical lab test to analyze for mutations in the VH or variable region of the Immunoglobulin heavy chain locus, also known as IGH@. | 180 | $290 | $50.9K |
| 81450 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as blood or bone marrow, for DNA and possibly RNA alterations in five to 50 genes known to impact… | 70 | $740 | $50.6K |
| 86235 | The lab analyst performs an assay to evaluate the patient’s serum for each antibody to an extractable nuclear antigen, also called ENA. Types of ENA antibodies include anti ribonuclear protein,… | 2,780 | $20 | $50K |
| 84402 | The lab analyst performs a test to measure free testosterone, typically in patient serum. | 1,910 | $30 | $47.6K |
| 81270 | The lab analyst performs the technical lab test to detect the presence of a common change in the gene for Janus kinase 2, also known as JAK2. | 400 | $90 | $35.6K |
| 84207 | The lab analyst performs a test to evaluate the level of pyridoxal phosphate, also called PLP, or vitamin B6, in a patient specimen such as plasma. | 1,230 | $30 | $33.3K |
| 84403 | The lab analyst performs a test to measure total testosterone, typically in patient serum. | 1,270 | $30 | $31.8K |
| 81256 | The lab analyst performs the technical lab test to detect the presence of common changes in the hemochromatosis gene, also known as HFE. | 490 | $60 | $31.2K |
Showing 1–10 of 291
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 291 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
291 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81479 | 3 | 10 | 770 | $1,680 | $10.4M |
| 87798 | 3 | 10 | 480 | $30 | $226.9K |
| 81206 | 1 | 10 | 690 | $160 | $110.7K |
| 81450 | 2 | 10 | 70 | $740 | $54.3K |
| 81263 | 1 | 10 | 180 | $290 | $50.8K |
| 81270 | 1 | 10 | 400 | $90 | $35.5K |
| 81256 | 1 | 10 | 490 | $60 | $31.3K |
| G0480 | 2 | 10 | 70 | $110 | $30.5K |
| 82107 | 1 | 10 | 460 | $60 | $29K |
| 88350 | 12 | 10 | 220 | $60 | $26.1K |
Showing 1–10 of 291
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
268 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 13,370 | $70 | $869.2K |
| 83655 | The lab analyst performs a test to measure the amount of lead in the patient specimen. A typical aim of the test is to check for lead exposure. | 34,170 | $10 | $478.3K |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 1,790 | $220 | $390.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 12,200 | $30 | $317.1K |
| 84403 | The lab analyst performs a test to measure total testosterone, typically in patient serum. | 9,600 | $20 | $211.3K |
| 86235 | The lab analyst performs an assay to evaluate the patient’s serum for each antibody to an extractable nuclear antigen, also called ENA. Types of ENA antibodies include anti ribonuclear protein,… | 3,780 | $50 | $196.8K |
| 84402 | The lab analyst performs a test to measure free testosterone, typically in patient serum. | 8,640 | $20 | $181.4K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 2,760 | $60 | $165.6K |
| 86480 | The lab analyst performs a test to evaluate a cell mediated immunity gamma interferon antigen response to certain tuberculosis, or TB, antibodies. | 3,340 | $50 | $163.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,600 | $60 | $158.4K |
Showing 1–10 of 268
How this provider's Medicaid billing volume and revenue compare to other Utah providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Utah median
268 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81229 | The lab analyst performs the technical lab test using comparative genomic hybridization (CGH) microarray, also referred to as chromosomal microarray (CMA) or molecular karyotype performed by… | 2 | 10 | 20 | $990 | $4.2M |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 4 | 10 | 550 | $130 | $2.8M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 20 | 660 | $60 | $625K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 10 | 70 | 1,610 | $30 | $367.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 6 | 20 | 270 | $40 | $334.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 40 | 770 | $90 | $231.9K |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 1 | 10 | 1,120 | $170 | $197.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 13 | 70 | 340 | $50 | $117.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2 | 10 | 230 | $80 | $89K |
| 86317 | The lab analyst performs an immunoassay to quantitate the patient’s specimen for antibodies to an infectious agent, not specified in another code. | 1 | 10 | 3,700 | $20 | $75.5K |
Showing 1–10 of 268
Other providers in the same ZIP code as Associated Regional And University Pathologists Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.